Balixafortide TFA (Synonyms: POL6326 TFA) |
カタログ番号GC39343 |
Balixafortide TFA (POL6326 TFA) は、IC50 が 10 nM 未満の、強力で選択的で忍容性の高いペプチド CXCR4 アンタゴニストです。 Balixafortide TFA は、CXCR7 を含む受容体の大きなパネルよりも CXCR4 に対して 1000 倍の選択性を示します。 Balixafortide TFA は、β-アレスチン動員とカルシウム流動を IC50 < 10 nM でブロックします。 Balixafortide TFA は、強力な造血幹細胞および前駆細胞 (HSPC) 動員剤でもあります。抗がん効果。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2].
[1]. Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103. [2]. Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2.
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *